Analytical Validation of a Deep Neural Network Algorithm for the Detection of Ovarian Cancer. (7th June 2022)

• Record Type: Journal Article
• Authors: Reilly, Gerard; Bullock, Rowan G.; Greenwood, Jessica; Ure, Daniel R.; Stewart, Erin; Davidoff, Pierre; DeGrazia, Justin; Fritsche, Herbert; Dunton, Charles J.; Bhardwaj, Nitin; Northrop, Lesley E.
• Is Part Of: JCO Clinical Cancer Informatics. Volume 6(2022)
• Publication Date: 2022-06-07
• Subjects: 616.994
• DOI: 10.1200/CCI.21.00192
• Languages: English
• ISSNs: 2473-4276

Abstract

Abstract : PURPOSE: Early detection of ovarian cancer, the deadliest gynecologic cancer, is crucial for reducing mortality. Current noninvasive risk assessment measures include protein biomarkers in combination with other clinical factors, which vary in their accuracy. Machine learning can be applied to optimizing the combination of these features, leading to more accurate assessment of malignancy. However, the low prevalence of the disease can make rigorous validation of these tests challenging and can result in unbalanced performance. METHODS: MIA3G is a deep feedforward neural network for ovarian cancer risk assessment, using seven protein biomarkers along with age and menopausal status as input features. The algorithm was developed on a heterogenous data set of 1, 067 serum specimens from women with adnexal masses (prevalence = 31.8%). It was subsequently validated on a cohort almost twice that size (N = 2, 000). RESULTS: In the analytical validation data set (prevalence = 4.9%), MIA3G demonstrated a sensitivity of 89.8% and a specificity of 84.02%. The positive predictive value was 22.45%, and the negative predictive value was 99.38%. When stratified by cancer type and stage, MIA3G achieved sensitivities of 94.94% for epithelial ovarian cancer, 76.92% for early-stage cancer, and 98.04% for late-stage cancer. CONCLUSION: The balanced performance of MIA3G leads to a high sensitivity and high specificity, a combination that may be clinically useful for providers in evaluating the appropriate management strategy for their patients. Limitations of this work include the largely retrospective nature of the data set and the unequal, albeit random, assignment of histologic subtypes between the training and validation data sets. Future directions may include the addition of new biomarkers or other modalities to strengthen the performance of the algorithm.